Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

NCT02440425 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Paclitaxel

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]